Literature DB >> 2433022

Cis-platinum (II) complexes of carboxymethyl-dextran as potential antitumor agents. II. In vitro and in vivo activity.

B Schechter, R Pauzner, M Wilchek, R Arnon.   

Abstract

Cis-diamminedichloro platinum (II) (cis-DDP) and cis-diamminediaquo platinum (II) nitrate (cis-aq) were complexed to a macromolecular carrier carboxymethyl dextran (CM-dex). Two carriers were used in this study, one derived from dex-T-10 (Mr-10000) and the other from dex-T-40 (Mr-40000). The two platinum (II) drugs formed soluble complexes with both carriers. Uncomplexed and complexed drugs were tested and found to be cytotoxic in vitro against 5 murine and 2 human derived tumor cell lines. The two free platinum (II) drugs were cytotoxic against these cells to a similar extent. In comparison to the free drugs the complexes were somewhat less active, up to 3 fold, against murine 38C-13, L1210, EL-4 and RDM-4 leukemias, as well as against human HeLa and osteogenic sarcoma, and as active as the free drugs against murine F9 embryonal carcinoma. There were no major differences in the in vitro cytotoxic activity between CM-dex T-10 and CM-dex T-40 complexes. Differences due to the molecular size of the carrier were observed in vivo: The CM-dex T-10 complexes were significantly less toxic than the free drugs, whereas the reduction of toxicity by complexing to CM-dex T-40 was less profound. As for the efficacy, when tested in vivo against a cis-DDP sensitive tumor (F9) the T-40 complexes were equally or even more effective than the respective free drugs. The T-10 complexes were less effective than the free drugs at equal drug doses but their effectivity increased at increasing drug levels. These complexes were, however, very effective in inhibiting tumor growth upon repeated injections, leading to 100% survival.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2433022

Source DB:  PubMed          Journal:  Cancer Biochem Biophys        ISSN: 0305-7232


  3 in total

1.  Selective cytotoxicity against tumor cells by cisplatin complexed to antitumor antibodies via carboxymethyl dextran.

Authors:  B Schechter; R Pauzner; R Arnon; J Haimovich; M Wilchek
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

2.  Blood levels and serum protein binding of cis-platinum(II) complexed to carboxymethyl-dextran.

Authors:  B Schechter; M A Rosing; M Wilchek; R Arnon
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 3.  Metal-based antibody drug conjugates. Potential and challenges in their application as targeted therapies in cancer.

Authors:  Virginia Del Solar; María Contel
Journal:  J Inorg Biochem       Date:  2019-07-18       Impact factor: 4.155

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.